| abstract |
Described is the combined use of a first antibody molecule that specifically binds FcyRIIb via its Fab region and that binds an Fey receptor via its Fc region, and a second antibody molecule that specifically binds PD-1 and that binds at least one Fey receptor via its Fc region, in the treatment of cancer in a patient having tumor infiltrating T lymphocytes with a medium or high PD-1 expression, as well as pharmaceutical compositions and kits comprising these two antibody molecules, and methods of treating cancer using these two antibodies. Described is also a diagnostic test for identification of patients benefitting from the treatment described herein. |